Treatment

Rigosertib Sodium Oral clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
This study is testing a new medicine, Rigosertib, for adults with a specific type of skin cancer linked to a skin condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB). Doctors want to see if the medicine can shrink the cancer and if it's safe to use.
For: Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Austria